Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

The TAM receptor TYRO3 is a critical regulator of myelin thickness in the central nervous system.

Blades F, Aprico A, Akkermann R, Ellis S, Binder MD, Kilpatrick TJ.

Glia. 2018 Oct;66(10):2209-2220. doi: 10.1002/glia.23481. Epub 2018 Sep 12.

PMID:
30208252
2.

Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study.

Stein MS, Ward GJ, Butzkueven H, Kilpatrick TJ, Harrison LC.

Mol Med. 2018 May 30;24(1):27. doi: 10.1186/s10020-018-0028-3.

3.

Technologies for Advanced Gait and Balance Assessments in People with Multiple Sclerosis.

Shanahan CJ, Boonstra FMC, Cofré Lizama LE, Strik M, Moffat BA, Khan F, Kilpatrick TJ, van der Walt A, Galea MP, Kolbe SC.

Front Neurol. 2018 Feb 2;8:708. doi: 10.3389/fneur.2017.00708. eCollection 2017. Review.

4.

Pharmacogenetic stimulation of neuronal activity increases myelination in an axon-specific manner.

Mitew S, Gobius I, Fenlon LR, McDougall SJ, Hawkes D, Xing YL, Bujalka H, Gundlach AL, Richards LJ, Kilpatrick TJ, Merson TD, Emery B.

Nat Commun. 2018 Jan 22;9(1):306. doi: 10.1038/s41467-017-02719-2.

5.

Achievements and obstacles of remyelinating therapies in multiple sclerosis.

Stangel M, Kuhlmann T, Matthews PM, Kilpatrick TJ.

Nat Rev Neurol. 2017 Dec;13(12):742-754. doi: 10.1038/nrneurol.2017.139. Epub 2017 Nov 17. Review.

6.

A Brain-Derived Neurotrophic Factor-Based p75NTR Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination.

Gonsalvez DG, Tran G, Fletcher JL, Hughes RA, Hodgkinson S, Wood RJ, Yoo SW, De Silva M, Agnes WW, McLean C, Kennedy P, Kilpatrick TJ, Murray SS, Xiao J.

eNeuro. 2017 Jul 4;4(3). pii: ENEURO.0142-17.2017. doi: 10.1523/ENEURO.0142-17.2017. eCollection 2017 May-Jun.

7.

Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤ 3.0.

Galea MP, Cofré Lizama LE, Butzkueven H, Kilpatrick TJ.

NeuroRehabilitation. 2017;40(2):277-284. doi: 10.3233/NRE-161413.

PMID:
28222549
8.

The TAM receptor Tyro3 regulates myelination in the central nervous system.

Akkermann R, Aprico A, Perera AA, Bujalka H, Cole AE, Xiao J, Field J, Kilpatrick TJ, Binder MD.

Glia. 2017 Apr;65(4):581-591. doi: 10.1002/glia.23113. Epub 2017 Feb 1.

PMID:
28145605
9.

A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180-190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice.

Gonsalvez DG, De Silva M, Wood RJ, Giuffrida L, Kilpatrick TJ, Murray SS, Xiao J.

J Neuropathol Exp Neurol. 2017 Feb 1;76(2):89-100. doi: 10.1093/jnen/nlw110.

PMID:
28082327
10.

Interleukin-2 receptor-α proximal promoter hypomethylation is associated with multiple sclerosis.

Field J, Fox A, Jordan MA, Baxter AG, Spelman T, Gresle M, Butzkueven H, Kilpatrick TJ, Rubio JP.

Genes Immun. 2017 Mar;18(2):59-66. doi: 10.1038/gene.2016.50. Epub 2017 Jan 12.

PMID:
28077880
11.

Stressful life events and the risk of initial central nervous system demyelination.

Saul A, Ponsonby AL, Lucas RM, Taylor BV, Simpson S Jr, Valery P, Dwyer T, Kilpatrick TJ, Pender MP, van der Mei IA.

Mult Scler. 2017 Jun;23(7):1000-1007. doi: 10.1177/1352458516667566. Epub 2016 Sep 6.

PMID:
27600112
12.

Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis.

Kolbe SC, van der Walt A, Butzkueven H, Klistorner A, Egan GF, Kilpatrick TJ.

J Ophthalmol. 2016;2016:2764538. doi: 10.1155/2016/2764538. Epub 2016 Jul 31.

13.

Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve.

Gresle MM, Liu Y, Kilpatrick TJ, Kemper D, Wu QZ, Hu B, Fu QL, So KF, Sheng G, Huang G, Pepinsky B, Butzkueven H, Mi S.

Mult Scler J Exp Transl Clin. 2016 Apr 19;2:2055217316641704. doi: 10.1177/2055217316641704. eCollection 2016 Jan-Dec.

14.

Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status.

Binder MD, Fox AD, Merlo D, Johnson LJ, Giuffrida L, Calvert SE, Akkermann R, Ma GZ; ANZgene, Perera AA, Gresle MM, Laverick L, Foo G, Fabis-Pedrini MJ, Spelman T, Jordan MA, Baxter AG, Foote S, Butzkueven H, Kilpatrick TJ, Field J.

PLoS Genet. 2016 Mar 18;12(3):e1005853. doi: 10.1371/journal.pgen.1005853. eCollection 2016 Mar.

15.

Fyn is an intermediate kinase that BDNF utilizes to promote oligodendrocyte myelination.

Peckham H, Giuffrida L, Wood R, Gonsalvez D, Ferner A, Kilpatrick TJ, Murray SS, Xiao J.

Glia. 2016 Feb;64(2):255-69. doi: 10.1002/glia.22927. Epub 2015 Oct 9.

PMID:
26449489
16.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
17.

Association of plasma levels of Protein S with disease severity in multiple sclerosis.

Ma GZ, Giuffrida LL, Gresle MM, Haartsen J, Laverick L, Butzkueven H, Field J, Binder MD, Kilpatrick TJ.

Mult Scler J Exp Transl Clin. 2015 Jul 24;1:2055217315596532. doi: 10.1177/2055217315596532. eCollection 2015 Jan-Dec.

18.

Population attributable fractions and joint effects of key risk factors for multiple sclerosis.

van der Mei I, Lucas RM, Taylor BV, Valery PC, Dwyer T, Kilpatrick TJ, Pender MP, Williams D, Chapman C, Otahal P, Ponsonby AL.

Mult Scler. 2016 Apr;22(4):461-9. doi: 10.1177/1352458515594040. Epub 2015 Jul 21.

PMID:
26199349
19.

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium, Wiley JS.

Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17.

PMID:
26188005
20.

Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor.

Gresle MM, Butzkueven H, Perreau VM, Jonas A, Xiao J, Thiem S, Holmes FE, Doherty W, Soo PY, Binder MD, Akkermann R, Jokubaitis VG, Cate HS, Marriott MP, Gundlach AL, Wynick D, Kilpatrick TJ.

Glia. 2015 Jun;63(6):1005-20. doi: 10.1002/glia.22798. Epub 2015 Jan 29.

PMID:
25639936
21.

Adult neural precursor cells from the subventricular zone contribute significantly to oligodendrocyte regeneration and remyelination.

Xing YL, Röth PT, Stratton JA, Chuang BH, Danne J, Ellis SL, Ng SW, Kilpatrick TJ, Merson TD.

J Neurosci. 2014 Oct 15;34(42):14128-46. doi: 10.1523/JNEUROSCI.3491-13.2014.

22.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
23.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
24.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
25.

Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution.

Gresle MM, Schulz K, Jonas A, Perreau VM, Cipriani T, Baxter AG, Miranda-Hernandez S, Field J, Jokubaitis VG, Cherny R, Volitakis I, David S, Kilpatrick TJ, Butzkueven H.

J Neurosci Res. 2014 Jun;92(6):732-42. doi: 10.1002/jnr.23349. Epub 2014 Jan 27.

PMID:
24615902
26.

Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes.

van der Walt A, Kolbe SC, Wang YE, Klistorner A, Shuey N, Ahmadi G, Paine M, Marriott M, Mitchell P, Egan GF, Butzkueven H, Kilpatrick TJ.

PLoS One. 2013 Dec 26;8(12):e83825. doi: 10.1371/journal.pone.0083825. eCollection 2013.

27.

Nanodiamonds with silicon vacancy defects for nontoxic photostable fluorescent labeling of neural precursor cells.

Merson TD, Castelletto S, Aharonovich I, Turbic A, Kilpatrick TJ, Turnley AM.

Opt Lett. 2013 Oct 15;38(20):4170-3. doi: 10.1364/OL.38.004170.

PMID:
24321951
28.

Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis.

Jokubaitis VG, Gresle MM, Kemper DA, Doherty W, Perreau VM, Cipriani TL, Jonas A, Shaw G, Kuhlmann T, Kilpatrick TJ, Butzkueven H.

Acta Neuropathol Commun. 2013 Jul 9;1:32. doi: 10.1186/2051-5960-1-32.

29.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group.

Brain. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18.

PMID:
24142147
30.

Inhibitory saccadic dysfunction is associated with cerebellar injury in multiple sclerosis.

Kolbe SC, Kilpatrick TJ, Mitchell PJ, White O, Egan GF, Fielding J.

Hum Brain Mapp. 2014 May;35(5):2310-9. doi: 10.1002/hbm.22329. Epub 2013 Sep 3.

PMID:
24038970
31.

The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: the Ausimmune study.

Ponsonby AL, Lucas RM, Dear K, van der Mei I, Taylor B, Chapman C, Coulthard A, Dwyer T, Kilpatrick TJ, McMichael AJ, Pender MP, Valery PC, Williams D.

Mult Scler. 2013 Nov;19(13):1717-25. doi: 10.1177/1352458513483887. Epub 2013 May 13.

PMID:
23670542
32.

Investigation of sequential growth factor delivery during cuprizone challenge in mice aimed to enhance oligodendrogliogenesis and myelin repair.

Sabo JK, Aumann TD, Kilpatrick TJ, Cate HS.

PLoS One. 2013 May 1;8(5):e63415. doi: 10.1371/journal.pone.0063415. Print 2013.

33.

Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially.

Hughes AM, Lucas RM, McMichael AJ, Dwyer T, Pender MP, van der Mei I, Taylor BV, Valery P, Chapman C, Coulthard A, Dear K, Kilpatrick TJ, Williams D, Ponsonby AL.

Clin Exp Immunol. 2013 Jun;172(3):466-74. doi: 10.1111/cei.12077.

34.

Occupational exposure and risk of central nervous system demyelination.

Valery PC, Lucas RM, Williams DB, Pender MP, Chapman C, Coulthard A, Dear K, Dwyer T, Kilpatrick TJ, McMichael AJ, van der Mei I, Taylor BV, Ponsonby AL.

Am J Epidemiol. 2013 May 1;177(9):954-61. doi: 10.1093/aje/kws361. Epub 2013 Apr 12.

PMID:
23585328
35.

Oligodendroglial expression of TrkB independently regulates myelination and progenitor cell proliferation.

Wong AW, Xiao J, Kemper D, Kilpatrick TJ, Murray SS.

J Neurosci. 2013 Mar 13;33(11):4947-57. doi: 10.1523/JNEUROSCI.3990-12.2013.

36.

Vitamin D status: multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient.

Lucas RM, Ponsonby AL, Dear K, Valery PC, Taylor B, van der Mei I, McMichael AJ, Pender MP, Chapman C, Coulthard A, Kilpatrick TJ, Stankovich J, Williams D, Dwyer T.

J Steroid Biochem Mol Biol. 2013 Jul;136:300-8. doi: 10.1016/j.jsbmb.2013.01.011. Epub 2013 Feb 8. Review.

PMID:
23395985
37.

EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE).

Munro KM, Dixon KJ, Gresle MM, Jonas A, Kemper D, Doherty W, Fabri LJ, Owczarek CM, Pearse M, Boyd AW, Kilpatrick TJ, Butzkueven H, Turnley AM.

PLoS One. 2013;8(2):e55948. doi: 10.1371/journal.pone.0055948. Epub 2013 Feb 4.

38.

A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination.

Xiao J, Hughes RA, Lim JY, Wong AW, Ivanusic JJ, Ferner AH, Kilpatrick TJ, Murray SS.

J Neurochem. 2013 May;125(3):386-98. doi: 10.1111/jnc.12168. Epub 2013 Feb 24.

39.

Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.

Wang Y, van der Walt A, Paine M, Klistorner A, Butzkueven H, Egan GF, Kilpatrick TJ, Kolbe SC.

PLoS One. 2012;7(12):e52291. doi: 10.1371/journal.pone.0052291. Epub 2012 Dec 18. Erratum in: PLoS One. 2012;7(12). doi: 10.1371/annotation/1c474016-06ef-4827-8fe8-82c158d7616b.

40.

Diffusion tensor imaging of acute inflammatory lesion evolution in multiple sclerosis.

Liu Y, Mitchell PJ, Kilpatrick TJ, Stein MS, Harrison LC, Baker J, Ditchfield M, Li K, Egan GF, Butzkueven H, Kolbe SC.

J Clin Neurosci. 2012 Dec;19(12):1689-94. doi: 10.1016/j.jocn.2012.03.022. Epub 2012 Oct 16.

PMID:
23084347
41.

Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS.

Koenning M, Jackson S, Hay CM, Faux C, Kilpatrick TJ, Willingham M, Emery B.

J Neurosci. 2012 Sep 5;32(36):12528-42. doi: 10.1523/JNEUROSCI.1069-12.2012.

42.

Extracellular signal-regulated kinase 1/2 signaling promotes oligodendrocyte myelination in vitro.

Xiao J, Ferner AH, Wong AW, Denham M, Kilpatrick TJ, Murray SS.

J Neurochem. 2012 Sep;122(6):1167-80. doi: 10.1111/j.1471-4159.2012.07871.x. Epub 2012 Aug 3.

43.

Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.

Oluich LJ, Stratton JA, Xing YL, Ng SW, Cate HS, Sah P, Windels F, Kilpatrick TJ, Merson TD.

J Neurosci. 2012 Jun 13;32(24):8317-30. doi: 10.1523/JNEUROSCI.1053-12.2012.

44.

A genome-wide association study in progressive multiple sclerosis.

Martinelli-Boneschi F, Esposito F, Brambilla P, Lindström E, Lavorgna G, Stankovich J, Rodegher M, Capra R, Ghezzi A, Coniglio G, Colombo B, Sorosina M, Martinelli V, Booth D, Oturai AB, Stewart G, Harbo HF, Kilpatrick TJ, Hillert J, Rubio JP, Abderrahim H, Wojcik J, Comi G.

Mult Scler. 2012 Oct;18(10):1384-94. Epub 2012 Mar 28.

PMID:
22457343
45.

Offspring number, pregnancy, and risk of a first clinical demyelinating event: the AusImmune Study.

Ponsonby AL, Lucas RM, van der Mei IA, Dear K, Valery PC, Pender MP, Taylor BV, Kilpatrick TJ, Coulthard A, Chapman C, Williams D, McMichael AJ, Dwyer T.

Neurology. 2012 Mar 20;78(12):867-74. doi: 10.1212/WNL.0b013e31824c4648. Epub 2012 Mar 7.

PMID:
22402857
46.

Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis.

Kolbe SC, Marriott M, Walt Av, Fielding J, Klistorner A, Mitchell PJ, Butzkueven H, Kilpatrick TJ, Egan GF.

Invest Ophthalmol Vis Sci. 2012 Feb 21;53(2):825-32. doi: 10.1167/iovs.11-8864.

PMID:
22247457
47.

Amine oxidase activity of β-amyloid precursor protein modulates systemic and local catecholamine levels.

Duce JA, Ayton S, Miller AA, Tsatsanis A, Lam LQ, Leone L, Corbin JE, Butzkueven H, Kilpatrick TJ, Rogers JT, Barnham KJ, Finkelstein DI, Bush AI.

Mol Psychiatry. 2013 Feb;18(2):245-54. doi: 10.1038/mp.2011.168. Epub 2012 Jan 3.

PMID:
22212595
48.

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.

Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI.

Ann Neurol. 2011 Dec;70(6):897-912. doi: 10.1002/ana.22609. Erratum in: Ann Neurol. 2013 Apr;73(4):561.

49.

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ.

Neurology. 2011 Oct 25;77(17):1611-8. doi: 10.1212/WNL.0b013e3182343274.

PMID:
22025459
50.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

Supplemental Content

Loading ...
Support Center